drugset / Trial / NCT00116870

MARS - Monitored Atherosclerosis Regression Study

NCT00116870

Phase 2/3 Completed 270 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether significant alterations in serum lipoproteins as provided by the drug lovastatin can substantially reduce atherosclerosis progression or even induce regression.

Timeline

Start
1985-06
Primary completion
1992-02
Completion
1992-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lovastatin Small molecule 40 mg